L-DOS47 Phase I Study Results To Be Presented at the 9th International Conference of Contemporary Oncology

TORONTO, ON–(Marketwired – Mar 21, 2017) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that results from the Phase I L-DOS47 study will be presented at the upcoming 9^th International Conference of Contemporary Oncology meeting in Poznan, Poland from the 22^nd to the 24^th of March, 2017. The leading theme of the conference is genome-based precision oncology — direct targeting and immune-targeting of cancer.

Trial investigator, Professor Cezary Szczylik from the Military Institute of Medicine will be presenting results on Friday, March 24^th, 2017 in the following session:

CLINICAL SESSION 8. PRECISION/PERSONALIZATION OF TARGETED THERAPY
13.40-14.15  Phase I/II dose escalation study of immunoconjugate L-DOS47 as a monotherapy in non-squamous non-small cell lung cancer patients

Also accepted for both oral and poster presentation on Wednesday, March 22^nd, 2017 is the session titled:

SESSION 2. PRECISION ONCOLOGY
17.30-17.55  Camelid single domain antibody application in cell based therapies

The presentations and posters will be posted to the Helix BioPharma Corp. website on the day of the presentation.

About LDOS002
LDOS002 is an open-label Phase I/II clinical study being conducted in Poland to evaluate the safety, tolerability and preliminary efficacy of ascending doses of L-DOS47, initially as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb/IV NSCLC. The study is being conducted at five Polish centers under the direction of Dr. Dariusz Kowalski at The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology as the overall coordinating investigator, together with four other principal investigators: Prof. Cezary Szczylik, MD, PhD at the Military Medical Institute, Prof. Elzbieta Wiatr, MD, PhD at the National Tuberculosis and Lung Diseases Research Institute, Dr. Aleksandra Szczensa, MD, PhD at the Mazovian Center of Pulmonary Diseases and Tuberculosis in Otwock and Prof. Rodryg Ramlau, MD, PhD at the Department of Oncology, Poznan University of Medical Science.

About L-DOS47
L-DOS47 is Helix’s first immunoconjugate-based drug candidate in development is based on Helix’s novel DOS47 technology platform which the Company believes alters the tumor microenvironment from acidic to alkaline and is positioning its core technology in the field of immuno-oncology as a unique Tumour Defence Breaker™. The Company believes L-DOS47 represents an innovative approach in modifying the microenvironmental conditions of cancer cells which the Company also believes serves as a general defense against cancer drugs and immunotherapies. Breaking the tumor defense by changing the tumor micro environment from acidic to alkaline represents one of the forgotten hallmarks of cancer. L-DOS47 is intended to offer an innovative approach to the first-line treatment of inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer. L-DOS47 is currently being evaluated in two clinical studies, one in the United States (“LDOS001”) and the other in Poland (“LDOS002”).

About Helix BioPharma Corp.
Helix BioPharma Corp. is an immune-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor (CAR) based cell therapies. Helix is currently listed on the TSX and FSE under the symbol “HBP”.

Cautionary Statements

This news release contains certain forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws, without limitation, those relating to unique Tumour Defense Breaker™, which may be identified by words including, without limitation, “unique”, “believes” “will”, “may”, “modifying”, “anticipated”, “intended”, “build”. “effective”, “continuing progress” and other similar expressions, are intended to provide information about management’s current plans and expectations.

Forward-looking statements include, without limitation, statements concerning (i) the Company’s ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company’s priority continuing to be L-DOS47; (iii) the Company’s development programs for DOS47 and L-DOS47; (iv) future expenditures, the insufficiency of the Company’s current cash resources and the need for financing; and (v) future financing requirements and the seeking of additional funding. Forward-looking statements can further be identified by the use of forward-looking terminology such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.

Forward-looking statements are statements about the future and are inherently uncertain, and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management’s current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release, including, but not limited to, the safety and efficacy of L-DOS47; that sufficient financing will be obtained in a timely manner to allow the Company to continue operations and implement its clinical trials in the manner and on the timelines anticipated; the timely provision of services and supplies or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; and the timely receipt of required regulatory approvals and strategic partner support.

The Company’s actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation, the risk that the Company’s assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company’s research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company’s anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in Helix’s Annual Information Form, in particular under the headings “Forward-looking Statements” and “Risk Factors”, and other reports filed under the Company’s profile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix’s management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.